GH Stock Overview
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Guardant Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.16 |
| 52 Week High | US$41.06 |
| 52 Week Low | US$15.81 |
| Beta | 0.90 |
| 1 Month Change | -3.00% |
| 3 Month Change | -25.71% |
| 1 Year Change | -20.85% |
| 3 Year Change | -89.32% |
| 5 Year Change | -74.13% |
| Change since IPO | -46.71% |
Recent News & Updates
Recent updates
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Guardant: Saving Lives One Blood Test At A Time
Oct 16Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt
Aug 15Guardant Health's test gets FDA win for companion diagnostic to Enhertu's expanded use in lung cancer
Aug 12Guardant Health: Recent Developments Signal More Upsides
Jul 31Guardant Health: Pending Recession, May Hurt Cancer Care Demand
Jul 14Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt
Apr 29Guardant Health: Leaping Growth With Epic
Apr 14Shareholder Returns
| GH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.9% | 0.6% | 1.0% |
| 1Y | -20.8% | 2.2% | 21.9% |
Return vs Industry: GH underperformed the US Healthcare industry which returned 3.4% over the past year.
Return vs Market: GH underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| GH volatility | |
|---|---|
| GH Average Weekly Movement | 9.7% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GH's share price has been volatile over the past 3 months.
Volatility Over Time: GH's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
| GH fundamental statistics | |
|---|---|
| Market cap | US$2.09b |
| Earnings (TTM) | -US$479.45m |
| Revenue (TTM) | US$563.95m |
3.7x
P/S Ratio-4.4x
P/E RatioIs GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GH income statement (TTM) | |
|---|---|
| Revenue | US$563.95m |
| Cost of Revenue | US$227.05m |
| Gross Profit | US$336.90m |
| Other Expenses | US$816.35m |
| Earnings | -US$479.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -3.94 |
| Gross Margin | 59.74% |
| Net Profit Margin | -85.02% |
| Debt/Equity Ratio | 718.4% |
How did GH perform over the long term?
See historical performance and comparison